Glucose Fluctuations Aggravate Myocardial Fibrosis via the Nuclear Factor-κB-Mediated Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation
暂无分享,去创建一个
Y. Liu | S. Dang | Ying Wu | Xiao-yan Li | Zhen-Ye Zhang | Ru-xing Wang | Miao-Miao Qi | L. Qian | Ning Wang | Ling-feng Miao | Shan-Shan Li | Chun-Xin Wang | Ru-Xing Wang
[1] T. Lüscher,et al. Inflammation in Metabolic Cardiomyopathy , 2021, Frontiers in Cardiovascular Medicine.
[2] Meenakshi Sharma,et al. Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes , 2021, International journal of molecular sciences.
[3] Q. Dai,et al. Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-κB/NLRP3 pathway. , 2020, Atherosclerosis.
[4] Jeroen J. Bax,et al. Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging , 2020, Nature Reviews Cardiology.
[5] L. Altucci,et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , 2020, Cardiovascular Diabetology.
[6] Q. Chai,et al. Glucose fluctuations promote vascular BK channels dysfunction via PKCα/NF-κB/MuRF1 signaling. , 2020, Journal of molecular and cellular cardiology.
[7] Y. Birnbaum,et al. Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay , 2020, Cardiovascular Drugs and Therapy.
[8] Zhenlian Wang,et al. NLRP3 Inflammasome and Inflammatory Diseases , 2020, Oxidative medicine and cellular longevity.
[9] Lu Lu,et al. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs. , 2019, European journal of pharmacology.
[10] Yi-mei Wang,et al. Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF‐&kgr;B/p38 signaling pathway in high‐fat diet/streptozotocin‐induced diabetic mice , 2018, International immunopharmacology.
[11] Baoping Chen,et al. Artesunate ameliorates high glucose-induced rat glomerular mesangial cell injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome pathway. , 2018, Chemico-biological interactions.
[12] E. Latz,et al. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. , 2018, Circulation research.
[13] W. Strain,et al. Diabetes, cardiovascular disease and the microcirculation , 2018, Cardiovascular Diabetology.
[14] Di Wang,et al. The NLRP3 inflammasome: Role in metabolic disorders and regulation by metabolic pathways. , 2018, Cancer letters.
[15] F. Huang,et al. NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy , 2017, Front. Physiol..
[16] Ting Liu,et al. Glucose variability aggravates cardiac fibrosis by altering AKT signalling path , 2017, Diabetes & vascular disease research.
[17] Antonio Abbate,et al. The inflammasome in myocardial injury and cardiac remodeling. , 2015, Antioxidants & redox signaling.
[18] T. Saikawa,et al. Glucose fluctuations increase the incidence of atrial fibrillation in diabetic rats. , 2014, Cardiovascular research.
[19] Yan Li,et al. Acute Blood Glucose Fluctuation Induces Myocardial Apoptosis through Oxidative Stress and Nuclear Factor-ĸB Activation , 2012, Cardiology.
[20] Sankar Ghosh,et al. Signaling to NF-kappaB. , 2004, Genes & development.
[21] R. Carmody,et al. NF-κB and the Transcriptional Control of Inflammation. , 2018, International review of cell and molecular biology.
[22] T. Saikawa,et al. Glucose Fluctuations Aggravate Cardiac Susceptibility to Ischemia/Reperfusion Injury by Modulating MicroRNAs Expression. , 2016, Circulation journal : official journal of the Japanese Circulation Society.